Support Alert

COVID-19 Therapeutic Alert

Withdrawal of the Recommendation for Consideration of Inhaled Budesonide as a Treatment Option for COVID-19

In parallel to the publication of revised guidance from the National Institute for Health and Care Excellence (NICE), the previously published UK interim position statement covering inhaled budesonide as a treatment option for individuals with COVID infection has been withdrawn.

Inhaled budesonide should no longer be considered as a treatment for COVID-19 infection other than within the context of a clinical trial. People already using budesonide for conditions other than COVID-19 should continue treatment if they test positive for COVID-19.

Further information and actions can be found in the alert.


Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.